- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Anti-PD-1 Treatment Selection
During this segment, Richard W. Joseph, MD, describes the effectiveness of the anti-PD-1 agents pembrolizumab and nivolumab, and discusses similarities and differences between the 2 drugs.
Dr Joseph explains that although no head-to-head trials have directly compared the 2 agents, cross-trial comparisons have demonstrated that they are similar in terms of safety and efficacy. For this reason, he questions why the FDA approved pembrolizumab after just a phase 1 study but required a phase 3 study prior to approving nivolumab.
One difference between the 2 drugs, he notes, is that while nivolumab is administered every 2 weeks, pembrolizumab is given every 3 weeks.
Dr Joseph suggests that unless proved otherwise, the agents should be considered equivalent by managed care organizations and payer coverage should be the same for both drugs.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
